检索结果-南通市图书馆

Journal of Geriatric Cardiology 2018年第10期15卷 639-643页

作者： George Kassimis Tushar Raina Department of Cardiology Cheltenham General HospitalGloucestershire Hospitals NHS Foundation TrustCheltenhamUnited Kingdom Second Department of Cardiology Hippokration HospitalMedieal SchoolAristotle University of ThessalonikiThessalonikiGreece

Compared with bare-metal stents (BMS),drug-eluting stems (DES)have shown better clinical outcomes for pa- tients undergoing percutaneous coronary intervention (PCI) by inhibition of neo-intirnal hyperplasia.[1]However,early- generation DES produced late thrombotic events,more than l-year,by delaying arterial healing of stented vessels,[2-5] New-generation DES have been developed'with thinner stent struts,more biocompatible polymer coatings for drug release,and a variety of antiproliferative agents with similar or superior anti-restenotic efficacy.[6]This development has led to a significant improvement in the efficacy and safety of new-generation DES,and consistently lower rates of very late stent thrombosis (VLST).[7,8]In fact,use of new-ge- neration DES is the standard treatment in contemporary PCI practice.[9]

关键词： Double vessel occlusion Myocardial infarction Very late stent thrombosis Zotarolimus eluting stents

Immediate and mid-term outcomes of drug-eluting stent in treatment of coronary artery stenosis with very long defuse lesions

在线全文

学校读者我要写书评

暂无评论

上海医学 2007年第S1期30卷 123-124页

作者： CHEN Lianglong, LIN Chaogui, PENG Yafei, ZHANG Feilong, ZHEN Xingchun, CHEN Jianhua, YAN Xiaoping , LUO Yukun. Union Hospital, Fujian Medical University & Fujian Provincial Institute of Coronary Disease, Fuzhou 350001,China

Objectives To evaluate the feasibility, and immediate and mid-term outcomes of drug-eluting stents (DESs) in the treatment of coronary artery stenosis with very long defuse lesions(VLDL). Methods Inclusion criteria:

关键词： stent stenosis eluting immediate angina VLDL lumen enrolled femoral severity

Sirolimus-eluting stent fractures associated with aneurysm and very late stent thrombosis in the right coronary artery

在线全文

学校读者我要写书评

暂无评论

上海医学 2007年第Z1期30卷 226-229页

作者： LIU Xuebo Gary S.Mintz Stéphane G.Carlier Martin B.Leon Department of Cardiology Zhongshan HospitalFudan University Columbia University Medical Center and Cardiovassular Research Faundation New York

Although the occurrence of coronary stent fracture is rare, recent reports showed that stent fracture after sirolimus-eluting stent (SES) implantation may be associated with neointimal hyperplasia and restenosis. We report two cases of stent fracture that occurred late after elective SES implantation into the right coronary artery (RCA) that were related to the aneurysm, restenosis, thrombosis, and vessel occlusion.

关键词： stent aneurysm eluting restenosis elective implantation distal occlusion longitudinal unstable

Atrial pacing lead:steroid-eluting and nonsteroid-eluting

在线全文

学校读者我要写书评

暂无评论

Chinese Medical Journal 1998年第5期 93-94页

作者：华伟

Ａｔｒｉａｌｐａｃｉｎｇｌｅａｄ：ｓｔｅｒｏｉｄｅｌｕｔｉｎｇａｎｄｎｏｎｓｔｅｒｏｉｄｅｌｕｔｉｎｇＨｕａＷｅｉ华伟ａｎｄＨａｒｙＭｏｎｄＦｕＷａｉＨｏｓｐｉｔａｌ，ＣｈｉｎｅｓｅＡｃａｄｅｍｙｏｆＭｅｄｉｃａ... 详细信息

Ａｔｒｉａｌｐａｃｉｎｇｌｅａｄ：ｓｔｅｒｏｉｄｅｌｕｔｉｎｇａｎｄｎｏｎｓｔｅｒｏｉｄｅｌｕｔｉｎｇＨｕａＷｅｉ华伟ａｎｄＨａｒｙＭｏｎｄＦｕＷａｉＨｏｓｐｉｔａｌ，ＣｈｉｎｅｓｅＡｃａｄｅｍｙｏｆＭｅｄｉｃａｌＳｃｉｅｎｃｅｓ，Ｂｅｉｊｉｎｇ...

关键词： eluting pacing steroid

Response rates of hepatocellular carcinoma and hepatic colorectal cancer metastases to drug eluting bead regional liver therapy

在线全文

学校读者我要写书评

暂无评论

Hepatoma Research 2017年第7期3卷 141-148页

作者： Glenn WStambo Deborah Cragan Department of Vascular and Interventional Florida HospitalTampaFL33614USA College of Public Health University of South FloridaTampaFL33612USA

Aim: The purpose of this study was to evaluate and compare how hepatocellular carcinoma (HCC) and colorectal metastases respond to LC Bead chemoembolization using doxorubicin and irinotecan. Methods: The authors report their experience with doxorubicin and irinotecan eluting beads to treat 13 patients with primary HCC and 25 patients with colorectal metastases over a 1-year period at a single community based oncology practice. Within the colorectal cancer group they compared irinotecan eluting beads to doxorubicin eluting beads. Results:Nine of the 11 (81.8%) doxorubicin treated HCC patients had either complete response or partial response. All of the HCC lesions showed reduction in size and tumor enhancement and 10/11 (91%) HCC patients were alive at 24 months post treatment. Fisher's exact test revealed that among the 22 with colorectal metastases for whom follow-up data were available, those 11 who were treated with doxorubicin were significantly more likely to demonstrate complete or partial response compared to the 11 in the irinotecan treated group (P eluting beads with 91% of the HCC patients alive 24 months after treatment.

关键词： Angiography transarterial chemoembolization drug eluting beads hepatocellular carcinoma doxorubicin irinotecan

Advantages and disadvantages of biodegradable platforms in drug eluting stents

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Cardiology 2011年第3期3卷 84-92页

作者： Agustina Rodriguez-Granillo Bibiana Rubilar Gaston Rodriguez-Granillo Alfredo E Rodriguez Center for Advanced Biotechnology and Medicine Rutgers University Staff Cardiac Unit Otamendi Hospital Intravascular Imaging Cardiac UnitOtamendi Hospital Cardiac Unit Otamendi HospitalCardiovascular Research Center(CECI)

Coronary angioplasty with drug-eluting stent(DES)implantation is currently the most common stent procedure *** the introduction of DES,coronary restenosis as well as the incidence of target vessel and target lesion revascularization have been significantly ***,the incidence of very late stent thrombosis beyond the first year after stent deployment has more commonly been linked to DES than to baremetal stent(BMS)*** factors have been associated with very late stent thrombosis after DES implantation,such as delayed healing,inflammation,stent mal-apposition and endothelial dysfunction. Some of these adverse events were associated with the presence of durable polymers,which were essential to allow the elution of the immunosuppressive drug in the first DES *** introduction of erodable polymers in DES technology has provided the potential to complete the degradation of the polymer simultaneously or immediately after the release of the immunosuppressive drug,after which a BMS remains in *** DES designs with biodegradable(BIO)polymers have been introduced in preclinical and clinical studies, including randomized *** this review,we analyze the clinical results from 6 observational and randomized studies with BIO polymers and discuss advantages and disadvantages of this new technology.

关键词： Polymers Drug eluting stents Biodegradable polymers Stents Thrombosis Restenosis

Safety and Efficacy of Ultra-Thin, Biodegradable Polymer Coated Sirolimus-eluting Supralimus-Core Stents in Real-World Patients: Outcomes at 24-Month Follow-Up

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Cardiovascular Diseases 2018年第11期8卷 523-532页

作者： Kala Jeethender Kumar Jain Subash Dasarapu Sai Satish Oruganti Jyotsna Maddury Srinivas Bhyravavajhala Rama Kumari Nuthalapati Vanaparthi Satya Bharathi Lakshmi Rajender Betham Anil Kumar Enikapalli Nizam’s Institute of Medical Sciences Hyderabad Telangana India

Aim: The purpose of this registry was to establish long-term safety and efficacy through implantation of Supralimus-Core sirolimus-eluting stents (SES) in real-world patients with coronary artery disease (CAD). Methods:The present registry was a retrospective, singe-arm, single-centre, investigator-initiated registry. A total of 372 consecutive patients were implanted with Supralimus-Core SES between January 2015 and November 2016. The primary endpoints were major adverse cardiac events (MACE), a composite of cardiac death, myocardial infarction (MI), target lesion revascularization (TLR) and target vessel revascularization (TVR) at 24 months. The secondary endpoints were all-cause death and all separate components of the primary endpoint. Additional endpoints included events of stent thrombosis classified as definite, probable, and possible stent thrombosis. Follow-ups were conducted at 30-days, 6-months, 12-months and 24-months after the index procedure. Results: The mean age of the registry population was 56.3 ± 11.1 years. Males constituted 276 (74.2%) patients. Hypertensives, diabetics, alcoholics, tobacco chewers and smokers comprised 198 (53.2%), 160 (43.0%), 93 (25.0%), 91 (24.5%) and 88 (23.7%) of the registry population, respectively. The mean length and diameter of stents implanted was 19.3 ± 8.8 mm and 2.9 ± 0.3 mm, respectively. At the 24-month follow-up, MACE was reported in 14 (3.8%) patients. Cardiac death, MI, TLR and TVR was reported in 7 (1.9%), 4 (1.1%), 3 (0.8%) and 4 (1.1%) patients, respectively. Overall stent thrombosis occurred in 4 (1.1%) patients. Conclusions: The low MACE rate of 3.8% at the 24-month follow-up indicates favorable long-term results after implantation of the ultra-thin strut Supralimus-Core SES in all-comer, real-world patients.

关键词： Biodegradable Polymer Cobalt-Chromium Coronary Artery Disease Drug eluting Stents Percutaneous Coronary Intervention Sirolimus-eluting Stent

Major clinical and angiographic outcome of drug eluting stents in native ostial coronary artery disease

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Cardiovascular Diseases 2013年第3期3卷 320-327页

作者： Khaled R. Abd El Meguid Hesham B. Mahmoud Fouad R. Amin Jonathan R. Clague Division of Cardiology Beni-Suef University Hospital Beni-Suef Egypt Division of Cardiology Heatherwood & Wexham Park Hospitals London UK Division of Cardiology Royal Brompton Hospital Imperial College London UK

Objectives: The study was designed to evaluate the efficacy and safety of drug eluting stents (DESs) in aorto-ostial (A-O) coronary artery lesions, in terms of early and late restenosis rate;including clinical assessment, non-invasive stress testing and angiographic follow-up. Also, the study was aimed to compare the results of implantation of drug eluting stents (DES) to that of bare metal stents (BMS) in aortoostial lesions done over a previous 5 years in Royal Brompton Hospital. Background: The safety and effectiveness of DESs for the treatment of aortoostial lesions. Methods: We included 161 consecutive patients with symptoms subjective of angina pectoris or objective evidence of myocardial ischemia;who underwent percutaneous coronary interventions (PCI) in coronary ostial lesions using DES. The patients were divided into two groups based on the site of ostial lesion. The control group consisted of 125 consecutive patients who underwent percutaneous coronary intervention for ostial lesions using bare metal stents (BMS) implantation in the period immediately before the introduction of DES. The incidence of major adverse cardiac events (MACE), including death or Q-wave myocardial infarction (MI), need for repeated revascularization procedure CABG or angioplasty, were recorded in-hospital and at twelve months ± 3 months. Follow-up angiography was only performed in case of recurrent symptoms subjective of myocardial ischemia or if there was objective evidence of myocardial ischemia by stress testing. Results: The initial procedure was successful in 149 patients (92.5%) in the DES arm. There were no statistically significant major in-hospital complications in the DES group, compared to BMS group which showed 4 cases of in-hospital deaths (p = 0.017). At Twelve months ± 3 months follow-up, MACE were significantly less frequent in the DES group compared to the BMS group, including death (0.8% vs. 6.4%, p = 0.004) and need for CABG (1.7% vs. 10%, p = 0.012). Conclusions

关键词： Bare Metal Stent DRUG eluting Stent Ostial Coronary Lesions

Seven Years Follow-Up of Biodegradable Polymer Coated Paclitaxel-eluting Infinnium Coronary Stent in Saudi Arabia

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

International Journal of Clinical Medicine 2014年第5期5卷 216-224页

作者： Layth Mimish Abdullateef Khoja Mohammad Anwar Vitek Rizniceck Taher Hasan Ashok Thakkar Bugshan Hospital Jeddah KSA King Abdulaziz University Jeddah KSA King Fahad Hospital Jeddah KSA Sahajanand Medical Technologies Pvt. Ltd. Surat India Soliman Fakeeh Hospital Jeddah KSA

Aim: In the present study, we analyzed 7-year clinical outcomes of patients included in the BIO degradable Polymer coated drug-eluting stent REgistry of Sahajanand Medical Technologies Pvt. Ltd. stents in Saudi Arabia (BIOPRESS)-Infinnium? registry. Methods: This was multicentre, observational, non-randomized, post-marketing surveillance registry, which included 276 consecutive patients treated with Infinnium? paclitaxel-eluting stent between July-2004 and June-2006. All patients underwent single-vessel or multiple-vessel percutaneous coronary intervention with high atherosclerotic risk factors and the patients were followed up to 7 years. Baseline and post-procedure angiographic follow-up were pre-specified in 231 patients. Results: The registry included 276 consecutive patients (81.5% male) with a mean age of 56.0 ± 11.1 years. Among 276 patients, diabetes and hypertension were present in 142 (51.4%) and 172 (62.3%) of patients respectively. Of all patients studied, 186 (67.4%) had single-vessel disease, 75 (27.2%) had double-vessel disease, and 15 (5.4%) had triple-vessel disease. Total 476 Infinnium? stents were implanted with an average stent length of 21.8 ± 7.5 mm. The incidence of major adverse cardiac events (MACE) up to 1 year was 26 (9.4%). Clinical follow-up was completed in 235 patients at seven-year follow-up. The data of seven-year clinical outcomes were as follow: cumulative MACE rate of 18.1% with 7.6% of total mortality and 3.6% of restenosis. Conclusion: These 7-year results of BIOPRESS-Infinnium? registry clearly provide evidence for safety and long-term effectiveness of the Infinnium? paclitaxel-eluting stent with the biodegradable polymer in real-life patients.

关键词： Coronary Artery Disease Paclitaxel eluting Stent Stent Thrombosis

Organ transplantation and drug eluting stents:Perioperative challenges

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Transplantation 2016年第4期6卷 620-631页

作者： Aparna Dalal Department of Anesthesiology Icahn School of Medicine

Patients listed for organ transplant frequently have severe coronary artery disease(CAD), which may be treated with drug eluting stents(DES). Everolimus and zotarolimus eluting stents are commonly used. Newer generation biolimus and novolimus eluting biodegradable stents are becoming increasingly popular. Patients undergoing transplant surgery soon after the placement of DES are at increased risk of stent thrombosis(ST) in the perioperative period. Dual antiplatelet therapy(DAPT) with aspirin and a P2Y12 inhibitor such as clopidogrel, prasugrel and ticagrelor is instated post stenting to decrease the incident of ST. Cangrelor has recently been approved by Food and Drug Administration and can be used as a bridging antiplatelet drug. The risk of ischemia vs bleeding must be considered when discontinuing or continuing DAPT for surgery. Though living donor transplant surgery is an elective procedure and can be optimally timed, cadaveric organ availability is unpredictable, therefore, discontinuation of antiplatelet medication cannot be optimally timed. The type of stent and timing of transplant surgery can be of utmost importance. Many platelet function point of care tests such as Light Transmittance Aggregrometry, Thromboelastography Platelet Mapping, VerifyN ow, Multiple Electrode Aggregrometry are used to assess bleeding risk and guide perioperative platelet transfusion. Response to allogenic platelet transfusion to control severe intraoperative bleeding may differ with the antiplatelet drug. In stent thrombosis is an emergency where management with either a drug eluting balloon or a DES has shown superior outcomes. Post-transplant complications often involved stenosis of an important vessel that may need revascularization. DES are now used for endovascular interventions for transplant orthotropic heart CAD, hepatic artery stenosis post liver transplantation, transplant renal artery stenosis following kidney transplantation, etc. Several antiproliferative drugs used

关键词： Drug eluting stents Cangrelor Stent thrombosis Organ transplant Antiplatelet medication Platelet function assays Mammalian target of rapamycin inhibitors Post-transplant immunosuppression Post-transplant endovascular inhibition Ticagrelor Thromboelastograms platelet mapping Novolimus Biolimus A9